Why MBX Biosciences, Inc.’s (MBX) Stock Is Up 5.40%
As of Thursday, July 23, MBX Biosciences, Inc.’s MBX share price has surged by 5.40%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Commentary & Analysis
Why MBX Biosciences, Inc.’s (MBX) Stock Is Up 6.43%
As of Friday, July 17, MBX Biosciences, Inc.’s MBX share price has surged by 6.43%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why MBX Biosciences, Inc.’s (MBX) Stock Is Down 5.50%
As of Tuesday, July 14, MBX Biosciences, Inc.’s MBX share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MBX Biosciences, Inc.’s (MBX) Stock Is Down 6.45%
As of Friday, July 10, MBX Biosciences, Inc.’s MBX share price has dipped by 6.45%, which has investors questioning if this is right time to buy.Jenna Brashear
Why MBX Biosciences, Inc.’s (MBX) Stock Is Up 7.07%
As of Thursday, July 09, MBX Biosciences, Inc.’s MBX share price has surged by 7.07%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MBX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,138.1 | $579.1 | 60% |
|
| Shares Out (Mil) | 46.6 | 43.0 | 46% |
|
| Institutional Ownership | 96.6% | 84.3% | 71% |
|
| Float (Mil) | 27.1 | 46.8 | 34% |
|
| Beta | na | 0.62 | na |
|
| Avg Daily Volume (000s) | 569 | 285 | 61% |
|
| Price Change (52-week) |
325.6% | 63.8% | 99% |
|
| Growth | MBX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | ($0.586) | ($2.713) | ($3.616) | |
| Month Ago EPS | ($0.602) | ($2.748) | ($3.935) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.650) | ($2.921) | ($4.097) | |
| Year/Year Chg | 16.0% | 13.9% | 81.6% | |
| Financials | MBX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($87) | ($11) | 12% |
|
| EPS (TTM) | ($2.176) | ($0.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($78) | ($6) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $16 | $4 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 14% |
|
| Enterprise Value (Q1) (Mil) | $1,468 | $522 | 46% |
|
| Valuation | MBX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.17 | 2.73 | 85% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | MBX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (24.8%) | (24.6%) | 19% |
|
| ROE | (25.7%) | (19.7%) | 22% |
|
| Liabilities to Assets | 3.3% | 35.5% | 1% |
|
| F-Score | 3 | 3 | 19% |
|
MBX Biosciences, Inc. did not pass any screens on 7/31/2026.
